Ra Capital Management, L.p. bought $1.7M of TYRA
director, owner at Tyra Biosciences, Inc.. 163,287 shares at an average of $10.19, traded Jun 12, 2025, filed Jun 16, 2025.
Score components
- +15RoleDirector
- +25Trade size$1.7M at market
- 0Relative to holdingsHoldings up 1.6%
- +8Price context64% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying3 buys in 90 days
- -5Track recordMedian 6-month excess return -38% over 3 past buys
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-017446, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 12, 2025 | POpen-market purchase Common Stockindirect: See footnotes | +31,307 | $10.20 | $319k | 10,127,311 | Jun 16, 2025 |
| Jun 13, 2025 | POpen-market purchase Common Stockindirect: See footnotes | +120,167 | $10.20 | $1.2M | 10,247,478 | Jun 16, 2025 |
| Jun 16, 2025 | POpen-market purchase Common Stockindirect: See footnotes | +11,813 | $10.13 | $120k | 10,259,291 | Jun 16, 2025 |
Related signals
Other insiders at Tyra Biosciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 31Weak | TYRAbuy Tyra Biosciences, Inc. | Rehan Verjee director | $20k 972 shares | - | |
| 16Weak | Tyra Biosciences, Inc. | Robert J More director | $250k 10,000 shares | -0% | |
| 15Weak | Tyra Biosciences, Inc. | Daniel Bensen Chief Discovery Officer | $181k 8,000 shares | -5% | |
| 28Weak | Tyra Biosciences, Inc. | Robert J More director | $5.0M 246,871 shares | -6% | |
| 43Moderate | Tyra Biosciences, Inc. | Daniel Bensen Chief Operating Officer | $2.0M 125,589 shares | -42% | |
| 43Moderate | Tyra Biosciences, Inc. | Daniel Bensen Chief Operating Officer | $2.1M 131,411 shares | -31% | |
| 35Weak | TYRAsell Tyra Biosciences, Inc. | Gilla Kaplan director | $94k 9,578 shares | -25% | |
| 53Moderate | TYRAsell Tyra Biosciences, Inc. | Gilla Kaplan director | $535k 51,814 shares | -58% | |
| 48Moderate | TYRAbuy Tyra Biosciences, Inc. | Ra Capital Management, L.p. director, owner | $1.9M 186,850 shares | +2% | |
| 46Moderate | TYRAbuy Tyra Biosciences, Inc. | Ra Capital Management, L.p. director, owner | $12M 1,211,198 shares | +14% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.